Targeting the th17 pathway in psoriasis

Journal of Leukocyte Biology

Volumn 92, Issue 6, 2012, Pages 1187-1197

  Merle Elloso, M ^a   Gomez Angelats, Mireia ^a   Fourie, Anne M ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Interleukin 17; Interleukin 23; ROR t; Vitamin D receptor

Indexed keywords

APILIMOD; BRIAKINUMAB; BRODALUMAB; CALCIPOTRIOL; CNTO1959; DIGOXIN; ETANERCEPT; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; IXEKIZUMAB; MK3222; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; RUXOLITINIB; SECUKINUMAB; TOFACITINIB; UNCLASSIFIED DRUG; URSOLIC ACID; USTEKINUMAB; VIDOFLUDIMUS;

CELLULAR IMMUNITY; CYTOKINE PRODUCTION; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; REVIEW; TH17 CELL;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; PSORIASIS; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84870466814     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0212101     Document Type: Review

References (106)

1. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., Coffman, R. L. (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357.
2. Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., Cua, D. J. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240.
3. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., Stockinger, B. (2006) TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189.
4. McGeachy, M. J., Chen, Y., Tato, C. M., Laurence, A., Joyce-Shaikh, B., Blumenschein, W. M., McClanahan, T. K., O'Shea, J. J., Cua, D. J. (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 10, 314-324.
5. Annunziato, F., Romagnani, S. (2011) Mouse T helper 17 phenotype: not so different than in man after all. Cytokine 56, 112-115.
6. Harris, T. J., Grosso, J. F., Yen, H. R., Xin, H., Kortylewski, M., Albesiano, E., Hipkiss, E. L., Getnet, D., Goldberg, M. V., Maris, C. H., Housseau, F., Yu, H., Pardoll, D. M., Drake, C. G. (2007) Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol. 179, 4313-4317.
7. Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., Littman, D. R. (2006) The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121-1133.
8. Yang, X. O., Panopoulos, A. D., Nurieva, R., Chang, S. H., Wang, D., Watowich, S. S., Dong, C. (2007) STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282, 9358-9363.
9. Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang, H. S., Chung, Y., Ma, L., Shah, B., Panopoulos, A. D., Schluns, K. S., Watowich, S. S., Tian, Q., Jetten, A. M., Dong, C. (2008) T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and ROR γ. Immunity 28, 29-39.
10. Gaffen, S. L. (2009) Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9, 556-567.
11. Chang, S. H., Dong, C. (2007) A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell. Res. 17, 435-440.
12. Liang, S. C., Long, A. J., Bennett, F., Whitters, M. J., Karim, R., Collins, M., Goldman, S. J., Dunussi-Joannopoulos, K., Williams, C. M., Wright, J. F., Fouser, L. A. (2007) An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J. Immunol. 179, 7791-7799.
13. Wright, J. F., Guo, Y., Quazi, A., Luxenberg, D. P., Bennett, F., Ross, J. F., Qiu, Y., Whitters, M. J., Tomkinson, K. N., Dunussi-Joannopoulos, K., Carreno, B. M., Collins, M., Wolfman, N. M. (2007) Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J. Biol. Chem. 282, 13447-13455.
14. Ishigame, H., Kakuta, S., Nagai, T., Kadoki, M., Nambu, A., Komiyama, Y., Fujikado, N., Tanahashi, Y., Akitsu, A., Kotaki, H., Sudo, K., Nakae, S., Sasakawa, C., Iwakura, Y. (2009) Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30, 108-119.
15. Yang, X. O., Chang, S. H., Park, H., Nurieva, R., Shah, B., Acero, L., Wang, Y. H., Schluns, K. S., Broaddus, R. R., Zhu, Z., Dong, C. (2008) Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205, 1063-1075.
16. Yao, Z., Painter, S. L., Fanslow, W. C., Ulrich, D., Macduff, B. M., Spriggs, M. K., Armitage, R. J. (1995) Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155, 5483-5486.
17. Cua, D. J., Tato, C. M. (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 10, 479-489.
18. Ma, C. S., Chew, G. Y., Simpson, N., Priyadarshi, A., Wong, M., Grimbacher, B., Fulcher, D. A., Tangye, S. G., Cook, M. C. (2008) Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 205, 1551-1557.
19. Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., Gumbleton, M., Toulon, A., Bodemer, C., El-Baghdadi, J., Whitters, M., Paradis, T., Brooks, J., Collins, M., Wolfman, N. M., Al-Muhsen, S., Galicchio, M., Abel, L., Picard, C., Casanova, J. L. (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65-68.
20. Yao, Z., Spriggs, M. K., Derry, J. M., Strockbine, L., Park, L. S., Vanden- Bos, T., Zappone, J. D., Painter, S. L., Armitage, R. J. (1997) Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9, 794-800.
21. Toy, D., Kugler, D., Wolfson, M., Vanden Bos, T., Gurgel, J., Derry, J., Tocker, J., Peschon, J. (2006) Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol. 177, 36-39.
22. Kuestner, R. E., Taft, D. W., Haran, A., Brandt, C. S., Brender, T., Lum, K., Harder, B., Okada, S., Ostrander, C. D., Kreindler, J. L., Aujla, S. J., Reardon, B., Moore, M., Shea, P., Schreckhise, R., Bukowski, T. R., Presnell, S., Guerra-Lewis, P., Parrish-Novak, J., Ellsworth, J. L., Jaspers, S., Lewis, K. E., Appleby, M., Kolls, J. K., Rixon, M., West, J. W., Gao, Z., Levin, S. D. (2007) Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J. Immunol. 179, 5462-5473.
23. Sun, D., Novotny, M., Bulek, K., Liu, C., Li, X., Hamilton, T. (2011) Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat. Immunol. 12, 853-860.
24. Bulek, K., Liu, C., Swaidani, S., Wang, L., Page, R. C., Gulen, M. F., Herjan, T., Abbadi, A., Qian, W., Sun, D., Lauer, M., Hascall, V., Misra, S., Chance, M. R., Aronica, M., Hamilton, T., Li, X. (2011) The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat. Immunol. 12, 844-852.
25. Lee, J., Ho, W. H., Maruoka, M., Corpuz, R. T., Baldwin, D. T., Foster, J. S., Goddard, A. D., Yansura, D. G., Vandlen, R. L., Wood, W. I., Gurney, A. L. (2001) IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J. Biol. Chem. 276, 1660-1664.
26. Chang, S. H., Reynolds, J. M., Pappu, B. P., Chen, G., Martinez, G. J., Dong, C. (2011) Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35, 611-621.
27. Ramirez-Carrozzi, V., Sambandam, A., Luis, E., Lin, Z., Jeet, S., Lesch, J., Hackney, J., Kim, J., Zhou, M., Lai, J., Modrusan, Z., Sai, T., Lee, W., Xu, M., Caplazi, P., Diehl, L., de Voss, J., Balazs, M., Gonzalez Jr., L., Singh, H., Ouyang, W., Pappu, R. (2011) IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat. Immunol. 12, 1159-1166.
28. Song, X., Zhu, S., Shi, P., Liu, Y., Shi, Y., Levin, S. D., Qian, Y. (2011) IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat. Immunol. 12, 1151-1158.
29. Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., Pin, J. J., Garrone, P., Garcia, E., Saeland, S., Blanchard, D., Gaillard, C., Das Mahapatra, B., Rouvier, E., Golstein, P., Banchereau, J., Lebecque, S. (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183, 2593-2603.
30. Perera, G.K., Di Meglio, P., Nestle, F. O. (2012) Psoriasis. Annu. Rev. Pathol. 7, 385-422.
31. Johansen, C., Usher, P. A., Kjellerup, R. B., Lundsgaard, D., Iversen, L., Kragballe, K. (2009) Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br. J. Dermatol. 160, 319-324.
32. Li, J., Chen, X., Liu, Z., Yue, Q., Liu, H. (2007) Expression of Th17 cytokines in skin lesions of patients with psoriasis. J. Huazhong Univ. Sci. Technolog. Med. Sci. 27, 330-332.
33. Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., Krueger, J. G. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128, 1207-1211.
34. Teunissen, M. B., Koomen, C. W., de Waal Malefyt, R., Wierenga, E. A., Bos, J. D. (1998) Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111, 645-649.
35. Kagami, S., Rizzo, H. L., Lee, J. J., Koguchi, Y., Blauvelt, A. (2010) Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 130, 1373-1383.
36. Nograles, K. E., Zaba, L. C., Guttman-Yassky, E., Fuentes-Duculan, J., Suarez-Farinas, M., Cardinale, I., Khatcherian, A., Gonzalez, J., Pierson, K. C., White, T. R., Pensabene, C., Coats, I., Novitskaya, I., Lowes, M. A., Krueger, J. G. (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159, 1092-1102.
37. Pene, J., Chevalier, S., Preisser, L., Venereau, E., Guilleux, M. H., Ghannam, S., Moles, J. P., Danger, Y., Ravon, E., Lesaux, S., Yssel, H., Gascan, H. (2008) Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J. Immunol. 180, 7423-7430.
38. Chan, J. R., Blumenschein, W., Murphy, E., Diveu, C., Wiekowski, M., Abbondanzo, S., Lucian, L., Geissler, R., Brodie, S., Kimball, A. B., Gorman, D. M., Smith, K., de Waal Malefyt, R., Kastelein, R. A., McClanahan, T. K., Bowman, E. P. (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203, 2577-2587.
39. Lee, S., French, M. A., Price, P. (2004) IL-23 and IFN-γ deficiency in immunodeficient HIV patients who achieved a long-term increase in CD4 T-cell counts on highly active antiretroviral therapy. AIDS 18, 1337-1340.
40. Piskin, G., Sylva-Steenland, R. M., Bos, J. D., Teunissen, M. B. (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176, 1908-1915.
41. δ T cells in skin inflammation. Immunity 35, 596-610.
42. Res, P. C., Piskin, G., de Boer, O. J., van der Loos, C. M., Teeling, P., Bos, J. D., Teunissen, M. B. (2010) Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 5, e14108.
43. Hueber, A. J., Asquith, D. L., Miller, A. M., Reilly, J., Kerr, S., Leipe, J., Melendez, A. J., McInnes, I. B. (2010) Mast cells express IL-17A in rheumatoid arthritis synovium. J. Immunol. 184, 3336-3340.
44. Ortega, C., Fernandez, A. S., Carrillo, J. M., Romero, P., Molina, I. J., Moreno, J. C., Santamaria, M. (2009) IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J. Leukoc. Biol. 86, 435-443.
45. Cargill, M., Schrodi, S. J., Chang, M., Garcia, V. E., Brandon, R., Callis, K. P., Matsunami, N., Ardlie, K. G., Civello, D., Catanese, J. J., Leong, D. U., Panko, J. M., McAllister, L. B., Hansen, C. B., Papenfuss, J., Prescott, S. M., White, T. J., Leppert, M. F., Krueger, G. G., Begovich, A. B. (2007) A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273-290.
46. Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., Blauvelt, A. (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J. Invest. Dermatol. 129, 2175-2183.
47. Homey, B., Dieu-Nosjean, M. C., Wiesenborn, A., Massacrier, C., Pin, J. J., Oldham, E., Catron, D., Buchanan, M. E., Muller, A., DeWaal Malefyt, R., Deng, G., Orozco, R., Ruzicka, T., Lehmann, P., Lebecque, S., Caux, C., Zlotnik, A. (2000) Up-regulation of macrophage inflammatory protein-3 α/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164, 6621-6632.
48. Liang, S. C., Tan, X. Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., Fouser, L. A. (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203, 2271-2279.
49. Tonel, G., Conrad, C., Laggner, U., Di Meglio, P., Grys, K., McClanahan, T. K., Blumenschein, W. M., Qin, J. Z., Xin, H., Oldham, E., Kastelein, R., Nickoloff, B. J., Nestle, F. O. (2010) Cutting edge: a critical functional role for IL-23 in psoriasis. J. Immunol. 185, 5688-5691.
50. Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., Ouyang, W. (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445, 648-651.
51. Rizzo, H. L., Kagami, S., Phillips, K. G., Kurtz, S. E., Jacques, S. L., Blauvelt, A. (2011) IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J. Immunol. 186, 1495-1502.
52. Nakajima, K., Kanda, T., Takaishi, M., Shiga, T., Miyoshi, K., Nakajima, H., Kamijima, R., Tarutani, M., Benson, J. M., Elloso, M. M., Gutshall, L. L., Naso, M. F., Iwakura, Y., DiGiovanni, J., Sano, S. (2011) Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J. Immunol. 186, 4481-4489.
53. Ghoreschi, K., Laurence, A., Yang, X. P., Hirahara, K., O'Shea, J. J. (2011) T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol. 32, 395-401.
54. Zaba, L. C., Fuentes-Duculan, J., Eungdamrong, N. J., Abello, M. V., Novitskaya, I., Pierson, K. C., Gonzalez, J., Krueger, J. G., Lowes, M. A. (2009) Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J. Invest. Dermatol. 129, 79-88.
55. Toichi, E., Torres, G., McCormick, T. S., Chang, T., Mascelli, M. A., Kauffman, C. L., Aria, N., Gottlieb, A. B., Everitt, D. E., Frederick, B., Pendley, C. E., Cooper, K. D. (2006) An anti-IL-12p40 antibody downregulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177, 4917-4926.
56. Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., Gordon, K. B. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665-1674.
57. Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M. C., Wang, Y., Li, S., Dooley, L. T., Reich, K. (2008) Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684.
58. Griffiths, C. E., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus- Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., Dooley, L. T., Goldstein, N. H., Menter, A. (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118-128.
59. Reich, K., Langley, R. G., Papp, K. A., Ortonne, J. P., Unnebrink, K., Kaul, M., Valdes, J. M. (2011) A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N. Engl. J. Med. 365, 1586-1596.
60. Gordon, K. B., Langley, R. G., Gottlieb, A. B., Papp, K. A., Krueger, G. G., Strober, B. E., Williams, D. A., Gu, Y., Valdes, J. M. (2012) A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J. Invest. Dermatol. 132, 304-314.
61. Traczewski, P., Rudnicka, L. (2012) Briakinumab for the treatment of plaque psoriasis. BioDrugs 26, 9-20.
62. Hueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., Durez, P., Tak, P. P., Gomez- Reino, J. J., Foster, C. S., Kim, R. Y., Samson, C. M., Falk, N. S., Chu, D. S., Callanan, D., Nguyen, Q. D., Rose, K., Haider, A., Di Padova, F. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72.
63. Genovese, M. C., Van den Bosch, F., Roberson, S. A., Bojin, S., Biagini, I. M., Ryan, P., Sloan-Lancaster, J. (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, doubleblind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62, 929-939.
64. Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson- Heredia, E., Braun, D., Banerjee, S. (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366, 1190-1199.
65. Papp, K. A., Leonardi, C., Menter, A., Ortonne, J. P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H., Baumgartner, S. (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181-1189.
66. van der Fits, L., Mourits, S., Voerman, J. S., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A. M., Florencia, E., Prens, E. P., Lubberts, E. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182, 5836-5845.
67. Solt, L. A., Griffin, P. R., Burris, T. P. (2010) Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeutics. Curr. Opin. Lipidol. 21, 204-211.
68. Ichiyama, K., Yoshida, H., Wakabayashi, Y., Chinen, T., Saeki, K., Nakaya, M., Takaesu, G., Hori, S., Yoshimura, A., Kobayashi, T. (2008) Foxp3 inhibits RORγt-mediated IL-17A mRNA transcription through direct interaction with RORγt. J. Biol. Chem. 283, 17003-17008.
69. Giguere, V., Tini, M., Flock, G., Ong, E., Evans, R. M., Otulakowski, G. (1994) Isoform-specific amino-terminal domains dictate DNA-binding properties of RORγ, a novel family of orphan hormone nuclear receptors. Genes Dev. 8, 538-553.
70. Jetten, A. M., Kurebayashi, S., Ueda, E. (2001) The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog. Nucleic Acids Res. Mol. Biol. 69, 205-247.
71. Huh, J. R., Leung, M. W., Huang, P., Ryan, D. A., Krout, M. R., Malapaka, R. R., Chow, J., Manel, N., Ciofani, M., Kim, S. V., Cuesta, A., Santori, F. R., Lafaille, J. J., Xu, H. E., Gin, D. Y., Rastinejad, F., Littman, D. R. (2011) Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 472, 486-490.
72. Solt, L. A., Kumar, N., Nuhant, P., Wang, Y., Lauer, J. L., Liu, J., Istrate, M. A., Kamenecka, T. M., Roush, W. R., Vidovic, D., Schurer, S. C., Xu, J., Wagoner, G., Drew, P. D., Griffin, P. R., Burris, T. P. (2011) Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472, 491-494.
73. Xu, T., Wang, X., Zhong, B., Nurieva, R. I., Ding, S., Dong, C. (2011) Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORγ t protein. J. Biol. Chem. 286, 22707-22710.
74. Kumar, N., Lyda, B., Chang, M. R., Lauer, J. L., Solt, L. A., Burris, T. P., Kamenecka, T. M., Griffin, P. R. (2012) Identification of SR2211: a potent synthetic RORγ-selective modulator. ACS Chem. Biol. 7, 672-677.
75. Solt, L. A., Kumar, N., He, Y., Kamenecka, T. M., Griffin, P. R., Burris, T. P. (2012) Identification of a selective RORγ ligand that suppresses T(H)17 cells and stimulates T regulatory cells. ACS Chem. Biol., Epub ahead of print.
76. Nagpal, S., Na, S., Rathnachalam, R. (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 26, 662-687.
77. McCormack, P. L. (2011) Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp. Drugs 71, 709-730.
78. Na, S., Ma, Y., Zhao, J., Schmidt, C., Zeng, Q. Q., Chandrasekhar, S., Chin, W. W., Nagpal, S. (2011) A nonsecosteroidal vitamin D receptor modulator ameliorates experimental autoimmune encephalomyelitis without causing hypercalcemia. Autoimmune Dis. 2011, 132958.
79. Joshi, S., Pantalena, L. C., Liu, X. K., Gaffen, S. L., Liu, H., Rohowsky- Kochan, C., Ichiyama, K., Yoshimura, A., Steinman, L., Christakos, S., Youssef, S. (2011) 1,25-Dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol. Cell. Biol. 31, 3653-3669.
80. Ikeda, U., Wakita, D., Ohkuri, T., Chamoto, K., Kitamura, H., Iwakura, Y., Nishimura, T. (2010) 1α,25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunol. Lett. 134, 7-16.
81. Chen, Z., Laurence, A., O'Shea, J. J. (2007) Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin. Immunol. 19, 400-408.
82. Murray, P. J. (2007) The JAK-STAT signaling pathway: input and output integration. J. Immunol. 178, 2623-2629.
83. Ghoreschi, K., Laurence, A., O'Shea, J. J. (2009) Janus kinases in immune cell signaling. Immunol. Rev. 228, 273-287.
84. Mohr, A., Chatain, N., Domoszlai, T., Rinis, N., Sommerauer, M., Vogt, M., Muller-Newen, G. (2012) Dynamics and non-canonical aspects of JAK/STAT signalling. Eur. J. Cell Biol. 91, 524-532.
85. Ishizaki, M., Akimoto, T., Muromoto, R., Yokoyama, M., Ohshiro, Y., Sekine, Y., Maeda, H., Shimoda, K., Oritani, K., Matsuda, T. (2011) Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/ Th17 axes in vivo. J. Immunol. 187, 181-189.
86. Minegishi, Y., Saito, M., Morio, T., Watanabe, K., Agematsu, K., Tsuchiya, S., Takada, H., Hara, T., Kawamura, N., Ariga, T., Kaneko, H., Kondo, N., Tsuge, I., Yachie, A., Sakiyama, Y., Iwata, T., Bessho, F., Ohishi, T., Joh, K., Imai, K., Kogawa, K., Shinohara, M., Fujieda, M., Wakiguchi, H., Pasic, S., Abinun, M., Ochs, H. D., Renner, E. D., Jansson, A., Belohradsky, B. H., Metin, A., Shimizu, N., Mizutani, S., Miyawaki, T., Nonoyama, S., Karasuyama, H. (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745-755.
87. Tefferi, A., Pardanani, A. (2011) JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 25, 229-237.
88. Fridman, J. S., Scherle, P. A., Collins, R., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B., Collier, P., Favata, M. F., Wen, X., Shi, J., McGee, R., Haley, P. J., Shepard, S., Rodgers, J. D., Yeleswaram, S., Hollis, G., Newton, R. C., Metcalf, B., Friedman, S. M., Vaddi, K. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 184, 5298-5307.
89. Meyer, D. M., Jesson, M. I., Li, X., Elrick, M. M., Funckes-Shippy, C. L., Warner, J. D., Gross, C. J., Dowty, M. E., Ramaiah, S. K., Hirsch, J. L., Saabye, M. J., Barks, J. L., Kishore, N., Morris, D. L. (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J. Inflamm. (Lond.) 7, 41.
90. Moran, N. (2012) Incyte comes of age with JAK inhibitor approval. Nat. Biotechnol. 30, 3-5.
91. Punwani, N., Scherle, P., Flores, R., Shi, J., Liang, J., Yeleswaram, S., Levy, R., Williams, W., Gottlieb, A. (2012) Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J. Am. Acad. Dermatol., Epub ahead of print.
92. Fridman, J. S., Scherle, P. A., Collins, R., Burn, T., Neilan, C. L., Hertel, D., Contel, N., Haley, P., Thomas, B., Shi, J., Collier, P., Rodgers, J. D., Shepard, S., Metcalf, B., Hollis, G., Newton, R. C., Yeleswaram, S., Friedman, S. M., Vaddi, K. (2011) Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J. Invest. Dermatol. 131, 1838-1844.
93. Boy, M. G., Wang, C., Wilkinson, B. E., Chow, V. F., Clucas, A. T., Krueger, J. G., Gaweco, A. S., Zwillich, S. H., Changelian, P. S., Chan, G. (2009) Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J. Invest. Dermatol. 129, 2299-2302.
94. Kremer, J. M., Cohen, S., Wilkinson, B. E., Connell, C. A., French, J. L., Gomez-Reino, J., Gruben, D., Kanik, K. S., Krishnaswami, S., Pascual- Ramos, V., Wallenstein, G., Zwillich, S. H. (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64, 970-981.
95. Ghoreschi, K., Jesson, M. I., Li, X., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., Thomas, C. J., Minnerly, J. C., Storer, C. E., LaBranche, T. P., Radi, Z. A., Dowty, M. E., Head, R. D., Meyer, D. M., Kishore, N., O'Shea, J. J. (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186, 4234-4243.
96. Fitzpatrick, L. R., Deml, L., Hofmann, C., Small, J. S., Groeppel, M., Hamm, S., Lemstra, S., Leban, J., Ammendola, A. (2010) 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm. Bowel Dis. 16, 1763-1777.
97. Kulkarni, O. P., Sayyed, S. G., Kantner, C., Ryu, M., Schnurr, M., Sardy, M., Leban, J., Jankowsky, R., Ammendola, A., Doblhofer, R., Anders, H. J. (2010) 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL- (Fas)lpr mice. Am. J. Pathol. 176, 2840-2847.
98. Chiba, K. (2007) [A new orally active anti-rheumatic drug targets IL-15 and IL-17]. Nihon Rinsho Meneki Gakkai Kaishi 30, 375-382.
99. Wada, Y., Lu, R., Zhou, D., Chu, J., Przewloka, T., Zhang, S., Li, L., Wu, Y., Qin, J., Balasubramanyam, V., Barsoum, J., Ono, M. (2007) Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood 109, 1156-1164.
100. Sands, B. E., Jacobson, E. W., Sylwestrowicz, T., Younes, Z., Dryden, G., Fedorak, R., Greenbloom, S. (2010) Randomized, double-blind, placebo- controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm. Bowel Dis. 16, 1209-1218.
101. Krausz, S., Boumans, M. J., Gerlag, D. M., Lufkin, J., van Kuijk, A. W., Bakker, A., de Boer, M., Lodde, B. M., Reedquist, K. A., Jacobson, E. W., O'Meara, M., Tak, P. P. (2012) Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an IL-12/IL-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 64, 1750-1755.
102. Brand, S. (2009) Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58, 1152-1167.
103. Langley, R. G., Strober, B. E., Gu, Y., Rozzo, S. J., Okun, M. M. (2010) Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br. J. Dermatol. 162, 1349-1358.
104. Lubberts, E. (2008) IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41, 84-91.
105. Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., Karczewski, J., Pezous, N., Bek, S., Bruin, G., Mellgard, B., Berger, C., Londei, M., Bertolino, A. P., Tougas, G., Travis, S. P. (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut Epub ahead of print.
106. Sandborn, W. J., Feagan, B. G., Fedorak, R. N., Scherl, E., Fleisher, M. R., Katz, S., Johanns, J., Blank, M., Rutgeerts, P. (2008) A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135, 1130-1141.